VIRGINIA RETIREMENT SYSTEMS ET Al Purchases Shares of 867,311 Edwards Lifesciences Corporation $EW

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 867,311 shares of the medical research company’s stock, valued at approximately $67,832,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.15% of Edwards Lifesciences at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $27,000. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $28,000. Tradewinds Capital Management LLC raised its holdings in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after buying an additional 205 shares in the last quarter. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

EW opened at $74.50 on Friday. The business’s 50-day moving average price is $77.54 and its two-hundred day moving average price is $76.19. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00. The company has a market capitalization of $43.74 billion, a price-to-earnings ratio of 10.72, a P/E/G ratio of 3.58 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the business posted $0.70 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Argus upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Thursday, July 10th. Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Finally, Evercore ISI set a $88.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.